NGM Biopharmaceuticals (NASDAQ:NGM) Trading Down 1.3%

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) fell 1.3% on Monday . The stock traded as low as $1.54 and last traded at $1.54. 2,390,800 shares were traded during trading, an increase of 63% from the average session volume of 1,467,160 shares. The stock had previously closed at $1.56.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. TD Cowen reaffirmed a “market perform” rating and set a $1.55 target price (down previously from $4.00) on shares of NGM Biopharmaceuticals in a research note on Wednesday, February 28th. B. Riley cut NGM Biopharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 28th. Citigroup reaffirmed a “neutral” rating on shares of NGM Biopharmaceuticals in a research note on Tuesday, February 27th. Finally, Raymond James lowered NGM Biopharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 12th.

NGM Biopharmaceuticals Stock Performance

The firm has a fifty day moving average price of $1.56 and a 200 day moving average price of $1.20. The stock has a market cap of $128.53 million, a PE ratio of -0.90 and a beta of 1.27.

NGM Biopharmaceuticals (NASDAQ:NGM) last released its earnings results on Monday, March 11th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.04. NGM Biopharmaceuticals had a negative return on equity of 77.85% and a negative net margin of 3,223.34%. The firm had revenue of $0.17 million for the quarter, compared to the consensus estimate of $2.00 million. On average, equities research analysts forecast that NGM Biopharmaceuticals, Inc. will post -0.93 earnings per share for the current year.

Institutional Investors Weigh In On NGM Biopharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its position in shares of NGM Biopharmaceuticals by 12.8% during the 2nd quarter. BlackRock Inc. now owns 4,633,005 shares of the company’s stock valued at $11,999,000 after acquiring an additional 526,863 shares during the period. Vanguard Group Inc. boosted its holdings in shares of NGM Biopharmaceuticals by 14.6% during the 3rd quarter. Vanguard Group Inc. now owns 3,899,297 shares of the company’s stock worth $51,003,000 after purchasing an additional 496,089 shares during the last quarter. FMR LLC boosted its holdings in shares of NGM Biopharmaceuticals by 61.8% during the 2nd quarter. FMR LLC now owns 2,060,533 shares of the company’s stock worth $26,416,000 after purchasing an additional 787,347 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of NGM Biopharmaceuticals by 4.8% during the 3rd quarter. Acadian Asset Management LLC now owns 1,193,971 shares of the company’s stock worth $1,276,000 after purchasing an additional 55,128 shares during the last quarter. Finally, Euclidean Capital LLC boosted its holdings in shares of NGM Biopharmaceuticals by 32.9% during the 3rd quarter. Euclidean Capital LLC now owns 992,168 shares of the company’s stock worth $1,062,000 after purchasing an additional 245,494 shares during the last quarter. 75.74% of the stock is owned by institutional investors and hedge funds.

NGM Biopharmaceuticals Company Profile

NGM Biopharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis.